1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

Consumer Health Results Roundup: Genomma, Ipsen And Taisho

 
• By Tom Gallen

Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.

Red and blue arrow elevators with businessmen going up and down.

Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 7.5% to MXN1.48bn ($75.4m) in the second quarter, as turnover improved at single-digit rates in all three of its reporting regions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

France’s Boiron Looks To Future After Challenging Year

 
• By Tom Gallen

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.

Reducing Complexity Helps Weleda Break Sales Record

 
• By Tom Gallen

Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.

End Of Year Recovery Ensures Recordati’s OTC Business Keeps Growing

 
• By Tom Gallen

Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.

More from Business

France’s Boiron Looks To Future After Challenging Year

 
• By Tom Gallen

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.

Over The Counter: Evolving The UK Consumer Health Industry, With PAGB’s Michelle Riddalls

 
• By David Ridley

HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.

Reducing Complexity Helps Weleda Break Sales Record

 
• By Tom Gallen

Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.